Clinical trial · Observational
Cancer Genome Analysis
NCT01458704CI-TRIAL-00005682unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Next generation sequencing (including targeted gene seqeuncing, exome and transcriptome sequencing) will be performed from fresh frozen tumor samples to understand the genetic alteration of tumors and to aid in optimal selection of further therapeutic agents.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumor | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| next generation sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- fresh frozen tumor tissue
- description
- patients providing fresh frozen tumor tissue
- interventionNames
- Other: next generation sequencing
Primary outcomes (1)
- measure
- targeted sequencing of cancer-relate genes
- timeFrame
- 1 year
- description
- Identification and characterization of genetic alteration in cancer tissue
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with malignant tumor * receiving or planning to receive chemotherapy * with fresh frozen tumor tissue * with informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.